Clash of Oral P2Y12 Receptor Inhibitors in Acute Coronary Syndromes.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2017.12.004
Abstract: SEE PAGE 371 P 2Y12 receptors on platelet membrane are key modulators of platelet aggregation and thrombosis in acute coronary syndromes (2). Oral P2Y12 receptor inhibitors (clopidogrel, ticagrelor, and prasugrel) combined with aspirin (dual antiplatelet… read more here.
Keywords: receptor inhibitors; oral p2y12; acute coronary; coronary syndromes ... See more keywords
TCT-808 Comparison between Clopidogrel and the New Oral P2Y12 Inhibitors in the Treatment of Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2018.08.2043
Abstract: Dual antiplatelet therapy improves angiographic results of primary percutaneous coronary intervention (pPCI) in patients with STEMI. The new oral P2Y12 inhibitors (P2Y12-I) prasugrel and ticagrelor are the gold-standard drugs because of a faster and more… read more here.
Keywords: oral p2y12; primary percutaneous; percutaneous coronary; coronary intervention ... See more keywords
Timing of Oral P2Y12 Inhibitor Administration in Non-ST Elevation Acute Coronary Syndrome.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2020.08.053
Abstract: BACKGROUND Although oral P2Y12 inhibitors are key in the management of patients with non-ST elevation acute coronary syndrome (NSTE-ACS), the optimal timing of their administration is not well defined. OBJECTIVE to compare downstream and upstream… read more here.
Keywords: administration; p2y12; cardiology; oral p2y12 ... See more keywords
Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial.
Sign Up to like & getrecommendations! Published in 2019 at "Resuscitation"
DOI: 10.1016/j.resuscitation.2019.02.008
Abstract: AIMS Cangrelor has a potentially favorable pharmacodynamic profile in cardiogenic shock (CS). We aimed to evaluate the clinical course of CS patients undergoing percutaneous coronary intervention (PCI) treated with cangrelor. METHODS AND RESULTS We retrospectively… read more here.
Keywords: oral p2y12; iabp shock; cangrelor; cardiogenic shock ... See more keywords
Comparative efficacy and safety of oral P2Y12 inhibitors after non-ST-elevation acute coronary syndromes: a network meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Open Heart"
DOI: 10.1136/openhrt-2021-001937
Abstract: Background Currently, potent P2Y12 inhibition with the use of prasugrel or ticagrelor is the mainstay of treatment after an acute coronary syndrome (ACS). The 2020 European Society of Cardiology (ESC) Guidelines recommend the use of… read more here.
Keywords: ticagrelor; prasugrel; oral p2y12; nste acs ... See more keywords